ArticleJournal of oral and maxillofacial pathology : JOMFP
Validation of salivary microRNA 301a as a potential non-invasive diagnostic biomarker in gastric carcinoma.
Article in Journal of oral and maxillofacial pathology : JOMFP. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Early detection of cancer is key to good prognosis and improved survival rate. Gastric cancer (GC) is fatal and presents with poor prognosis as it is usually diagnosed only at advanced stages. Saliva is emerging as a preferred diagnostic tool due to its advantages of being non-invasive, easy to collect, and cost-effective. Salivary microRNAs (miRNA) are more reliable due to their stability, resistance to degradation and its abundant involvement in cancer progression. Aim: To estimate and validate the potential of salivary miRNA 301a in the diagnosis of Gastric cancer. Methods and Materials: This Cross-sectional study comprised of 60 GC patients (Group I) and 60 normal controls (Group II). Fold change (FC) values of serum and salivary miRNA301a levels were estimated using the Real Time-Polymerisation Chain Reaction (RT-PCR) and compared between the study groups. Correlation between the serum and salivary miRNA301a levels was also evaluated. MiRNA301a levels were compared and correlated, with the clinical stage and histopathological grades of GC. Results: The mean FC of serum (Mean ± SD = 2.62 ± 0.75, Mean Rank = 90.5) and salivary (Mean ± SD = 2.03 ± 0.56, Mean Rank = 90.5) miRNA301a was significantly higher in Gastric cancer patients compared to controls (Mean ± SD = 0.99 ± 0.004, Mean Rank = 30.5). Salivary miRNA301a levels exhibited significant positive correlation with serum miRNA301a in gastric cancer patients (r = 0.941). The mean FC of serum and salivary microRNA 301a exhibited significant correlation with the clinical stages and histopathological grades of GC. Conclusion: Salivary miRNA301a is a potential reliable diagnostic tool for early screening of Gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.